Article
Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
The Journal of molecular diagnostics : JMD - 1 Dec 2020
van 't Erve Iris, Greuter Marjolein J E, Bolhuis Karen, Vessies Daan C L, Leal Alessandro, Vink Geraldine R, van den Broek Daan, Velculescu Victor E, Punt Cornelis J A, Meijer Gerrit A, Coupé Veerle M H, Fijneman Remond J A
Abstract excerpt
Detection of KRAS, NRAS, and BRAF mutations in tumor tissue is currently used to predict resistance to treatment with anti-epidermal growth factor receptor (EGFR) antibodies in patients with metastatic colorectal cancer (mCRC). Liquid biopsies are minimally invasive, and cell-free circulating tumor DNA (ctDNA) mutation analyses may better represent tumor heterogeneity. This study examined the incorporation of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.